Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph J. Larosa Sells 1,866 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Regeneron Pharmaceuticals Trading Up 1.8 %

Shares of NASDAQ:REGN traded up $19.78 during trading on Friday, hitting $1,100.05. The company had a trading volume of 465,222 shares, compared to its average volume of 471,526. The stock has a market cap of $121.21 billion, a price-to-earnings ratio of 31.91, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a one year low of $715.22 and a one year high of $1,106.16. The company has a fifty day simple moving average of $1,010.86 and a two-hundred day simple moving average of $962.46. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on REGN shares. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Barclays upped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Wednesday. Argus upped their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Finally, UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,038.77.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Eudaimonia Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares during the last quarter. Team Hewins LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 11 shares during the last quarter. Angeles Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 11 shares during the period. Drive Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares during the period. Finally, MCF Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.